B+
Bull case
25%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
MMSI
Merit MedicalCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Q2 delivered 10% reported revenue growth, 9% organic constant-currency growth, higher GAAP and non-GAAP operating margins, and an 18% increase in non-GAAP EPS. Management said results exceeded the high end of expectations and raised 2026 revenue and non-GAAP EPS guidance, supporting a case for continued estimate resilience.
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-29 · AMC.
What can break
Failure to sustain Cardiac Therapies and Endoscopy growth could expose dependence on the strongest therapeutic categories and weaken the raised-guidance case. [#SEC-8K-2026-07-30]
Momentum
78
Value
57
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $93.00 · Bull $105.00 · Bear $72.00Analysis 2026-09-20; returns require an exact persisted reference.
Earnings
2026-10-29 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $101.64
Why
Momentum78 · Δ7d +13.5
Value57 · Δ7d -0.0
Sentiment46 · Δ7d -3.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-29 · AMC.
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Failure to sustain Cardiac Therapies and Endoscopy growth could expose dependence on the strongest therapeutic categories and weaken the raised-guidance case. [#SEC-8K-2026-07-30]
- • Raised full-year guidance increases execution risk if procedure demand, product mix, or margins soften before year-end. [#SEC-8K-2026-07-30]
- • Year-to-date operating cash flow declined 11% and free cash flow declined 14% despite stronger revenue and earnings.
Catalyst clock
2026-10-29 · AMC
Delivery against raised 2026 guidance
Lead driver: Value · See fundamentals
Momentum
78
8% active weight
Current posture
7d trendSoftening
Δ7d
+13.5
Δ21d
-2.2
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-1.1
Sentiment
46
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.8
Δ21d
-20.1
Why this grade
Composite grade C. Momentum 77.6 / Value 56.7 / Sentiment 46.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-20. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$93.00
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$5.57B
Beta
0.61
Shares Out
59.71M
P/E (TTM)
45.8
P/S (TTM)
3.59
P/FCF (TTM)
26.02
Rev YoY
+9.8%
EPS YoY
+20.3%
Gross Margin
+49.4%
Op Margin
+12.7%
Net Debt
$373.07M
Current Ratio
4.20
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data